MDCX: Medicus Pharma 3Q 2024 Financial Results Reported; Stock Now Trades Both in Canada and on Nasdaq After Completing an IPO in the U.S.

Zacks Small Cap Research11-27

By Steven Ralston, CFA NASDAQ:MDCX | TSXV:MDCX READ THE FULL MDCX RESEARCH REPORT READ THE FULL V.MDCX RESEARCH REPORT Third Quarter 2024 Financial Results On November 22, 2024, Medicus Pharma (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486768128?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GPhWNXzS7IGuQ6RUn6IU3g--~B/aD00OTg7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/a59bb4b8035314b835406479c0334d67","is_english":true,"pubTime":"2024-11-27 18:37","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486768128","market":"us","top_or_hot":-1,"title":"MDCX: Medicus Pharma 3Q 2024 Financial Results Reported; Stock Now Trades Both in Canada and on Nasdaq After Completing an IPO in the U.S.","media":"Zacks Small Cap Research","content":"<div>\n<p>By Steven Ralston, CFA\n NASDAQ:MDCX | TSXV:MDCX\nREAD THE FULL MDCX RESEARCH REPORT\nREAD THE FULL V.MDCX RESEARCH REPORT\nThird Quarter 2024 Financial Results\n\nOn November 22, 2024, Medicus Pharma (...</p>\n\n<a href=\"https://finance.yahoo.com/news/mdcx-medicus-pharma-3q-2024-103700902.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MDCX: Medicus Pharma 3Q 2024 Financial Results Reported; Stock Now Trades Both in Canada and on Nasdaq After Completing an IPO in the U.S.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMDCX: Medicus Pharma 3Q 2024 Financial Results Reported; Stock Now Trades Both in Canada and on Nasdaq After Completing an IPO in the U.S.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 18:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mdcx-medicus-pharma-3q-2024-103700902.html><strong>Zacks Small Cap Research</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Steven Ralston, CFA\n NASDAQ:MDCX | TSXV:MDCX\nREAD THE FULL MDCX RESEARCH REPORT\nREAD THE FULL V.MDCX RESEARCH REPORT\nThird Quarter 2024 Financial Results\n\nOn November 22, 2024, Medicus Pharma (...</p>\n\n<a href=\"https://finance.yahoo.com/news/mdcx-medicus-pharma-3q-2024-103700902.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/mdcx-medicus-pharma-3q-2024-103700902.html","article_id":"2486768128","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GPhWNXzS7IGuQ6RUn6IU3g--~B/aD00OTg7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/scr.zacks.com/a59bb4b8035314b835406479c0334d67"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486768128","pubTimestamp":1732703820,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On November 22, 2024, Medicus Pharma   reported financial results for the third quarter ending September 30, 2024.IPO in U.S. Provides Additional Funding & Common Stock that Trades on Nasdaq. On November 14, 2024, Medicus Pharma Ltd. closed an IPO  in the United States. Gross proceeds from the IPO were approximately US$4.0 million and consisted of 970,000 Units at a price of US$4.125 per Unit. Each Unit is comprised of 1 common share & one 5-year warrant exercisable at US$4.64 per share. The stock issued as part of the IPO trades under the same ticker in the U.S.  as in Canada , namely MDCX. The warrants are trading under the ticker MDCXW.Net proceeds from the IPO will help fund the Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded Dissolvable Microneedle Array SkinJect transdermal skin patch. Some of the net proceeds may be used to extend the Phase 2 trial to a pivotal trial and/or to expand to clinical trials covering other","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","QLD":"纳指两倍做多ETF","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","BK4104":"贸易公司与经销商","SQQQ":"纳指三倍做空ETF","MDCXW":"MEDICUS PHARMA LTD C/WTS (TO PUR COM)","MDCX":"Medicus Pharma Ltd.","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","TQQQ":"纳指三倍做多ETF","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股",".IXIC":"NASDAQ Composite","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BCC":"Boise Cascade L.L.C."},"translate_title":"MDCX：Medicus Pharma公布2024年第三季度财务业绩；在美国完成首次公开募股后，该股票现在在加拿大和纳斯达克交易。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCC":1,".IXIC":1,"NDAQ":1,"MDCX":1,"MDCXW":0.9,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"By Steven Ralston, CFA\n NASDAQ:MDCX | TSXV:MDCX\nREAD THE FULL MDCX RESEARCH REPORT\nREAD THE FULL V.MDCX RESEARCH REPORT\nThird Quarter 2024 Financial Results\n\nOn November 22, 2024, Medicus Pharma (NASDAQ:MDCX) (TSXV:MDCX) reported financial results for the third quarter ending September 30, 2024.\nStill being in the clinical trial stage, the company did not generate any revenues. With Medicus just having completed a reverse takeover transaction last year on September 29, 2023, it is more appropriate to analyze the company’s operating expenses on a sequential basis. Professional fees were at a high level over the last two quarters (above $1.1 million), primarily due to higher legal and accounting fees related to the private placement. The fourth quarter should be impacted by the expenses for the U.S. IPO. Consulting fees have hovered in the $400,000 range every quarter this year with fluctuations due on the nature of the advisory services needed by the company. Salaries, wages and benefits oscillated between $200,000 and $340,000 depending on headcount. General office, insurance and administration expenditures have been relatively steady in the $150,000-to-$160,000 range with the exception of the second quarter where it appears that more insurance expenses and general office expenses were incurred. Investor relations have steadily increased quarter-by-quarter as management seeks to increase investor awareness of the company’s progress toward commercialization of SkinJect patch through its Phase 2 clinical trial now in progress.\n\nFor the third quarter, Medicus reported a net loss of $2.96 million (or $0.31 per diluted share) versus a net loss of approximately $2.96 million (or $0.85 per diluted share) in the comparable quarter last year. Shares outstanding increased by 173% YOY to 9,514,738 shares from 3,479,509 shares (adjusted for 1 for 2 consolidation). At quarter-end, Medicus had US$5.3 million cash-on-hand; moreover, the subsequent IPO in the U.S. added approximately US$3.64 million to the company’s coffer.\nIPO in U.S. Provides Additional Funding & Common Stock that Trades on Nasdaq\nOn November 14, 2024, Medicus Pharma Ltd. closed an IPO (Initial Public Offering) in the United States. Gross proceeds from the IPO were approximately US$4.0 million and consisted of 970,000 Units at a price of US$4.125 per Unit. Each Unit is comprised of 1 common share & one 5-year warrant exercisable at US$4.64 per share. The stock issued as part of the IPO trades under the same ticker in the U.S. (Nasdaq) as in Canada (TSXV), namely MDCX. The warrants are trading under the ticker MDCXW.\nNet proceeds from the IPO will help fund the Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded Dissolvable Microneedle Array SkinJect transdermal skin patch. Some of the net proceeds may be used to extend the Phase 2 trial to a pivotal trial and/or to expand to clinical trials covering other non-melanoma skin diseases. We estimate that the net proceeds from the IPO to be approximately US$3.64 million. Maxim Group LLC acted as the manager and Brookline Capital Markets (a division of Arcadia Securities, LLC) acted as co-manager.\nIn connection with the IPO, Medicus Pharma consolidated its common shares on a 2-to-1 basis on October 28th.\nNew Chief Medical Officer Appointed \nOn November 18, 2024, Dr. Faisal Mehmud, MD, was appointed Chief Medical Officer. Dr. Mehmud has had senior roles at several pharmaceutical companies, including Sanofi, Novartis, Bristol Myers Squibb, Pfizer and GlaxoSmithKline. Dr. Mehmud has a successful track record of advancing drugs in later phases in a variety of therapeutic areas, particularly in developing partnerships and interacting with regulators. Dr. Edward Brennan, MD, has been promoted to Chief Scientific Officer & Head of R&D Program.\nLatest News on Phase 2 Clinical Trial (SKNJCT-003)\nThe goal of the SKNJCT-003 Phase 2 clinical trial is to study the effectiveness of two different strengths of D-MNA (100μg and 200μg of doxorubicin hydrochloride) compared to placebo for the treatment of nodular basal cell skin cancer. The protocol is for a randomized, double-blinded, placebo-controlled clinical study with up to 60 patients with nodular BCC of the skin being enrolled at one of six (6) trial locations in the U.S.\nThe identified target lesion will be treated with a SkinJect patch once a week for three weeks. Then, after two weeks, the target lesion will be excised. An interim analysis is planned after about 28 subjects have completed the excision visit, which could potentially occur late in the fourth quarter of 2024. The SKNJCT-003 protocol follows the FDA guidelines for fast-tracking the approval process with its AI-powered protocol supported by confocal microscopy.\nThe official title of the clinical trial is “A Randomized, Double-Blinded, Placebo Controlled Trial to Evaluate the Safety and Efficacy of a Doxorubicin Microneedle Array (D-MNA) for the Treatment of Nodular Basal Cell Carcinoma in Adults.”\nOn August 27, 2024, Medicus Pharma announced that the first patient (of up to 60 subjects) had been randomized in the Phase 2 clinical trial (SKNJCT-003) for the treatment of nodular BCC (Basal Cell Carcinoma). This milestone indicates the culmination of the enrollment phase for first patient in this trial.\n\n\nOn July 15, 2024, Medicus Pharma announced that a full package of information was submitted to the FDA to support the approval for conducting a Phase 2 clinical trial (SKNJCT-003) on the company’s non-invasive treatment of basal cell carcinoma (BCC) of the skin that utilizes micro-needle arrays which contain doxorubicin.\nThe full comprehensive package of information was submitted in order to support an accelerated timeline of the FDA’s approval process. Management believes that by laying this groundwork. There is the potential ofconverting this exploratory Phase 2 trial into a pivotal trial through a Type C meeting with the FDA, hopefully in the 1Q 2025. If further alignment with the FDA can be achieved, management is hopeful that pivotal trial with 200-400 subjects can begin in 2Q 2025.\n\nValuation\nUtilizing a financial model based on DCF methodology, which forecasts out to 2031 and uses a 12% discount rate (based on CAPM), and a terminal P/S multiple of 2.79 (based on Specialty Drug Manufacturers that focus on developing and commercializing novel therapeutics for unmet healthcare needs), the indicated value of MDCX.V is CDN$7.83 per share, and on Nasdaq, the indicated value of MDCX is US$5.61.\nSUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. \n \nDISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486768128"}